Yesterday, April 4, 2016, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $300.52 to $2,835,525.00.

Highlighted Stocks Traded by Insiders:

Atossa Genetics (ATOS) - FREE Research Report

Remmel H. Lawrence, who is Director at Atossa Genetics, bought 1,500 shares at $0.33 on April 4, 2016. Following this transaction, the Director owned 10,900 shares meaning that the stake was boosted by 15.96% with the 1,500-share transaction.

The shares most recently traded at $0.28, down $0.05, or 17.86% since the insider transaction. Historical insider transactions for Atossa Genetics go as follows:

  • 4-Week # shares bought: 5,400
  • 12-Week # shares bought: 5,400
  • 24-Week # shares bought: 5,400

The average volume for Atossa Genetics has been 509,000 shares per day over the past 30 days. Atossa Genetics has a market cap of $9.7 million and is part of the health care sector and drugs industry. Shares are down 12.5% year-to-date as of the close of trading on Monday.

Atossa Genetics Inc. operates as a healthcare company that focuses on the development of a suite of laboratory services, medical devices, and therapeutics for breast cancer in the United States. The company markets nipple aspirate fluid (NAF) cytology tests and pharmacogenomics tests. Currently, there are 2 analysts who rate Atossa Genetics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATOS - FREE

TheStreet Quant Ratings

rates Atossa Genetics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Atossa Genetics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Egalet (EGLT) - FREE Research Report

Musial Stan, who is Chief Financial Officer at Egalet, sold 3,480 shares at $7.02 on April 4, 2016. Following this transaction, the Chief Financial Officer owned 94,940 shares meaning that the stake was reduced by 3.54% with the 3,480-share transaction.

Strobeck Mark, who is Chief Business Officer at Egalet, sold 8,700 shares at $6.70 on April 4, 2016. Following this transaction, the Chief Business Officer owned 89,280 shares meaning that the stake was reduced by 8.88% with the 8,700-share transaction.

Dayno Jeffrey M., who is Chief Medical Officer at Egalet, sold 536 shares at $6.72 on April 4, 2016. Following this transaction, the Chief Medical Officer owned 20,356 shares meaning that the stake was reduced by 2.57% with the 536-share transaction.

The shares most recently traded at $7.00, up $0.28, or 4% since the insider transaction. Historical insider transactions for Egalet go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 29,112

The average volume for Egalet has been 87,900 shares per day over the past 30 days. Egalet has a market cap of $172.8 million and is part of the health care sector and drugs industry. Shares are down 36.39% year-to-date as of the close of trading on Monday.

Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. Currently, there are 2 analysts who rate Egalet a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on EGLT - FREE

TheStreet Quant Ratings

rates Egalet as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full

Egalet Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Varonis Systems (VRNS) - FREE Research Report

Evergreen Iv L.P., who is 10% Owner at Varonis Systems, sold 3,459 shares at $18.47 on April 4, 2016. Following this transaction, the 10% Owner owned 3.4 million shares meaning that the stake was reduced by 0.1% with the 3,459-share transaction.

The shares most recently traded at $17.97, down $0.50, or 2.78% since the insider transaction. Historical insider transactions for Varonis Systems go as follows:

  • 4-Week # shares bought: 1,159
  • 4-Week # shares sold: 123,216
  • 12-Week # shares bought: 1,159
  • 12-Week # shares sold: 371,900
  • 24-Week # shares bought: 1,159
  • 24-Week # shares sold: 466,435

The average volume for Varonis Systems has been 170,700 shares per day over the past 30 days. Varonis Systems has a market cap of $477.7 million and is part of the technology sector and computer software & services industry. Shares are down 2.29% year-to-date as of the close of trading on Monday.

Varonis Systems, Inc. provides software platform for enterprises to analyze, secure, manage, and utilize their unstructured data. Currently, there are 3 analysts who rate Varonis Systems a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRNS - FREE

TheStreet Quant Ratings

rates Varonis Systems as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

Varonis Systems Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.